Literature DB >> 33159210

Shiga Toxin-Producing Escherichia coli Transmission via Fecal Microbiota Transplant.

Caroline Zellmer1, Mohamad R A Sater2, Miriam H Huntley2, Majdi Osman1, Scott W Olesen1, Bharat Ramakrishna1.   

Abstract

Fecal microbiota transplantation (FMT) is recommended therapy for multiply recurrent Clostridioides difficile infection. We report adverse events in 7 patients who received FMT from a stool donor who was colonized with Shiga toxin-producing Escherichia coli (STEC). No patients died of FMT-transmitted STEC. Improved screening can likely avoid future transmission.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Clostridioides difficilezzm321990 ; FMT; STEC; Shiga toxin-producing E. coli; fecal microbiota transplantation

Year:  2021        PMID： 33159210     DOI： 10.1093/cid/ciaa1486

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

1.  Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control.

Authors:  Laura Temime; Lulla Opatowski; David Rm Smith
Journal:  Elife       Date:  2021-09-14       Impact factor: 8.140

2.  High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection.

Authors:  Sang Hoon Lee; Han-Ki Park; Chang Don Kang; Dae Hee Choi; Sung Chul Park; Jin Myung Park; Seung-Joo Nam; Gi Bong Chae; Kyoung Yul Lee; Hyunseok Cho; Sung Joon Lee
Journal:  Front Cell Infect Microbiol       Date:  2022-06-06       Impact factor: 6.073

Review 3.  The Age of Next-Generation Therapeutic-Microbe Discovery: Exploiting Microbe-Microbe and Host-Microbe Interactions for Disease Prevention.

Authors:  Nathan Cruz; George A Abernathy; Armand E K Dichosa; Anand Kumar
Journal:  Infect Immun       Date:  2022-04-06       Impact factor: 3.609

Review 4.  Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients.

Authors:  Nirja Mehta; Tiffany Wang; Rachel J Friedman-Moraco; Cynthia Carpentieri; Aneesh K Mehta; Nadine Rouphael; Tanvi Dhere; Christian P Larsen; Colleen S Kraft; Michael H Woodworth
Journal:  J Clin Microbiol       Date:  2021-06-16       Impact factor: 11.677

Review 5.  Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls.

Authors:  Avnish Sandhu; Teena Chopra
Journal:  Therap Adv Gastroenterol       Date:  2021-12-23       Impact factor: 4.409

Review 6.  The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases.

Authors:  Rohma Ghani; Benjamin H Mullish; Lauren A Roberts; Frances J Davies; Julian R Marchesi
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 7.  Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study.

Authors:  Frederik Cold; Camilla Kara Svensson; Andreas Munk Petersen; Lars Hestbjerg Hansen; Morten Helms
Journal:  Cells       Date:  2022-01-27       Impact factor: 6.600

8.  Transmission of Antibiotic-Susceptible Escherichia coli Causing Urinary Tract Infections in a Fecal Microbiota Transplantation Recipient: Consequences for Donor Screening?

Authors:  Karuna E W Vendrik; Tim G J de Meij; Arend Bökenkamp; Rogier E Ooijevaar; Bas Groenewegen; Antoni P A Hendrickx; Elisabeth M Terveer; Ed J Kuijper; Joffrey van Prehn
Journal:  Open Forum Infect Dis       Date:  2022-06-29       Impact factor: 4.423

9.  Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient.

Authors:  Patricia P Bloom; John Donlan; Mariam Torres Soto; Michael Daidone; Elizabeth Hohmann; Raymond T Chung
Journal:  Hepatol Commun       Date:  2022-04-05

10.  Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.

Authors:  Robert Orenstein; Erik R Dubberke; Sahil Khanna; Christine H Lee; David Yoho; Stuart Johnson; Gail Hecht; Herbert L DuPont; Dale N Gerding; Ken F Blount; Sarah Mische; Adam Harvey
Journal:  BMC Infect Dis       Date:  2022-03-12       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.